Assignment text
OUS has chosen to enter into a contract with Theradis Pharma without a prior contest in order to avoid critical delay to the project, as Theradis Pharma already supplies equivalent services to the consortium EU RESPONSE. EU SolidAct is financed by the EU and will form part of Europe’s contingency plan for future pandemics. It is critical to implement the platform while COVID-19 is still a pandemic, as this can both be of significance in development of new treatments that can improve survival of COVID-19, as well as enable the EU to have quicker and better trialling of relevant medicines in the even of the next pandemic.